Journal
ONCOGENE
Volume 26, Issue 25, Pages 3614-3628Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1210378
Keywords
radioimmunotherapy; non-Hodgkin's lymphoma; tositumomab; ibritumomab; monoclonal antibodies; CD20
Ask authors/readers for more resources
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing - Y-90 ibritumomab tiuxetan and I-131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available